380 related articles for article (PubMed ID: 10770911)
1. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy.
Kaplan JE; Hanson D; Dworkin MS; Frederick T; Bertolli J; Lindegren ML; Holmberg S; Jones JL
Clin Infect Dis; 2000 Apr; 30 Suppl 1():S5-14. PubMed ID: 10770911
[TBL] [Abstract][Full Text] [Related]
2. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.
Jones JL; Hanson DL; Dworkin MS; Alderton DL; Fleming PL; Kaplan JE; Ward J
MMWR CDC Surveill Summ; 1999 Apr; 48(2):1-22. PubMed ID: 12412613
[TBL] [Abstract][Full Text] [Related]
3. Opportunistic infections and other AIDS-defining illnesses in Poland in 2000-2002.
Podlasin RB; Wiercinska-Drapalo A; Olczak A; Beniowski M; Smiatacz T; Malolepsza E; Juszczyk J; Leszczyszyn-Pynka M; Mach T; Mian M; Knysz B; Horban A
Infection; 2006 Aug; 34(4):196-200. PubMed ID: 16896577
[TBL] [Abstract][Full Text] [Related]
4. [Approach to opportunistic illness in the HAART era].
Imamura A
Nihon Rinsho; 2002 Apr; 60(4):757-62. PubMed ID: 11968784
[TBL] [Abstract][Full Text] [Related]
5. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
Pozio E
Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
[TBL] [Abstract][Full Text] [Related]
6. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
Ives NJ; Gazzard BG; Easterbrook PJ
J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
[TBL] [Abstract][Full Text] [Related]
7. Pneumocystis carinii pneumonia.
Schliep TC; Yarrish RL
Semin Respir Infect; 1999 Dec; 14(4):333-43. PubMed ID: 10638513
[TBL] [Abstract][Full Text] [Related]
8. I hear you knockin' (but you can't come in): potent new HIV therapies are shutting out opportunistic infections.
Fichtenbaum CJ
Res Initiat Treat Action; 1998 Jul; 4(4):3-7. PubMed ID: 11365645
[TBL] [Abstract][Full Text] [Related]
9. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
[TBL] [Abstract][Full Text] [Related]
10. Opportunistic infections: an update.
Furrer H; Fux C
J HIV Ther; 2002 Feb; 7(1):2-7. PubMed ID: 11956497
[TBL] [Abstract][Full Text] [Related]
11. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy.
Jacobson MA; French M
AIDS; 1998; 12 Suppl A():S157-63. PubMed ID: 9632998
[TBL] [Abstract][Full Text] [Related]
12. [Prevention of opportunistic infections in the protease inhibitor era].
Viciana P; Miralles-Martín P; Knobel H; Gatell JM
Enferm Infecc Microbiol Clin; 1998; 16 Suppl 1():1-10. PubMed ID: 9859614
[TBL] [Abstract][Full Text] [Related]
13. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.
López-Palomo C; Martín-Zamorano M; Benítez E; Fernández-Gutiérrez C; Guerrero F; Rodríguez-Iglesias M; Girón-González JA
J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752
[TBL] [Abstract][Full Text] [Related]
14. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy.
Dankner WM; Lindsey JC; Levin MJ;
Pediatr Infect Dis J; 2001 Jan; 20(1):40-8. PubMed ID: 11176565
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.
Weverling GJ; Mocroft A; Ledergerber B; Kirk O; Gonzáles-Lahoz J; d'Arminio Monforte A; Proenca R; Phillips AN; Lundgren JD; Reiss P
Lancet; 1999 Apr; 353(9161):1293-8. PubMed ID: 10218526
[TBL] [Abstract][Full Text] [Related]
16. Update on opportunistic infections.
Proj Inf Perspect; 1997 Nov; (23):16-7. PubMed ID: 11365373
[TBL] [Abstract][Full Text] [Related]
17. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.
Simonds RJ; Lindegren ML; Thomas P; Hanson D; Caldwell B; Scott G; Rogers M
N Engl J Med; 1995 Mar; 332(12):786-90. PubMed ID: 7862183
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.
Ylitalo N; Brogly S; Hughes MD; Nachman S; Dankner W; Van Dyke R; Seage GR;
Arch Pediatr Adolesc Med; 2006 Aug; 160(8):778-87. PubMed ID: 16894075
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology and risk of pulmonary disease.
Rosen MJ
Semin Respir Infect; 1999 Dec; 14(4):301-8. PubMed ID: 10638509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
